Belite Bio, Inc (BLTE) stock
Close on Nov 11, 2026Market cap $6.13BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- $6.13B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 7.96
- Dividend yield
- –
- Free cash flow yield
- -0.60%
Fundamentals
- Net income
- -$77.61M
- EPS, diluted
- -$2.31
- Free cash flow
- -$37.06M
Trading
- Previous close
- $156.52
- Open
- $157.01
- Day's range
- $155.03 – $158.25
- Volume
- 260,048
- Average volume (20 days)
- 158,782
- Beta (5 years)
- 0.17
- 52-week range
- $102.00 – $200.00
- RSI (14 days)
- 51.9
- Volatility (1 year)
- 53.9%
- Relative volume
- 1.47×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BLTE | S&P 500 | Difference | BLTE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +0.9% | -2.4% | +3.3 pts | ||
| 3 months | -12.2% | -1.2% | −11.0 pts | ||
| Year to date | -2.5% | +12.3% | −14.8 pts | ||
| 1 year | +47.4% | +12.4% | +35.0 pts | ||
| 3 years | +296.4% | +78.8% | +217.6 pts | +58.3% | +21.4% |
Seven years at a glance
Fiscal years 2019 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Belite Bio filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Belite Bio
Pharmaceutical Preparations
Belite Bio is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for debilitating retinal conditions with significant unmet needs. Its primary candidate is tinlarebant, an oral once-daily tablet designed to combat Geographic Atrophy associated with dry age-related macular degeneration and Stargardt disease type 1, which lead to progressive vision loss. The company's development pipeline also encompasses LBS-009, an oral small molecule aimed at treating metabolic disorders including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. Tinlarebant primarily targets adolescent and adult patients suffering from degenerative eye disorders.
Company profile, executives and historyBelite Bio stock: common questions
What is Belite Bio's stock price?
BLTE closed at $155.94 on Nov 11, 2026, down 0.37% on the day. Over the past 52 weeks it traded between $102.00 and $200.00.
What is Belite Bio's market cap?
Belite Bio was worth $6.13B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BLTE's P/E ratio?
Belite Bio lost money over fiscal 2025 (diluted EPS -$2.31), so it has no meaningful P/E ratio.
Does Belite Bio pay a dividend?
No. Belite Bio has not paid a cash dividend over the last twelve months.
How has BLTE stock performed over the past year?
Including dividends, BLTE returned +47.4% over the past year, against +12.4% for the S&P 500.
Who are Belite Bio's competitors?
Companies most similar to Belite Bio by business, industry and size include KPRX, LIANY, AARD, VRDN, VTVT.
See a number that looks wrong?